Skip to content

Sequencing: Sanger, NGS, and Long Reads

TL;DR

Sanger sequencing reads one targeted region at high per-read accuracy and remains useful for small validation tasks. NGS sequences millions of fragments in parallel and powers panels, exomes, genomes, RNA-seq, and single-cell assays. Long-read sequencing reads longer DNA/RNA molecules, helping with structural variants, repeats, phasing, isoforms, and methylation-aware workflows. Sources: [1], [2], [3]


Method comparison

MethodBest forWeakness
Sangersingle locus, plasmid, small validationlow throughput, poor for mixtures
Targeted NGS panelknown cancer genes, clinical depthlimited discovery outside panel
Exomecoding mutationsmisses noncoding and many structural events
Whole genomebroadest DNA viewcost, storage, interpretation
RNA-seqexpression, fusions, splicingRNA quality and expression bias
Long-readSVs, repeats, phasing, isoformscost, input quality, platform-specific error profile

What sequencing produces

Wet-lab stepData object
extractionconcentration, purity, integrity
library prepinsert size, adapter/index metadata
sequencingFASTQ reads and quality scores
alignmentBAM/CRAM
variant callingVCF/BCF
expression analysiscount matrix, TPM, differential expression

Common failure modes

  • degraded DNA/RNA
  • low tumor purity
  • formalin artifacts
  • index hopping or sample swaps
  • insufficient depth for low allele fraction
  • capture bias
  • PCR duplicates
  • poor reference alignment in repetitive regions
  • overinterpreting variants without orthogonal evidence

Developer notes

  • FASTQ is not "the sequence"; it is reads plus quality scores.
  • BAM/CRAM alignment depends on reference genome, aligner, parameters, and preprocessing.
  • VCF records are hypotheses after filtering, not raw truth.
  • Tumor-only sequencing needs special care because germline and somatic variants can be confused.
  • Long-read and short-read calls should not be merged blindly; they have different error profiles.
  • Every variant table should preserve sample, assay, genome build, caller, filtering, and depth metadata.

See also


References

  1. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-5467. https://doi.org/10.1073/pnas.74.12.5463
  2. Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed 2013;98:236-238. PMID 23986538. https://doi.org/10.1136/archdischild-2013-304340
  3. Si HQ, Wang P, Long F, et al. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA. Mol Cancer 2024;23:265. PMID 39614371. https://doi.org/10.1186/s12943-024-02178-6

Early public release. Content evolves through continuous review. Questions: [email protected] · CC BY 4.0 where applicable.